A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia

Name: A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia
Published: 2016
License: Public Domain

Celgene · 2016

ClinicalTrials.gov · Datasets · License: Public Domain · 2016

Open Source ↗

chronic immune-checkpoint leukemia lymphoma

lymphoma, leukemia, lymphocytic, chronic, b-cell, chronic lymphocytic leukemia, durvalumab, anti-pd-l1 antibody, medi4736, immune checkpoint, lymphatic disease, b-cell malignancies, abscopal effect, lenalidomide, bendamustine

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 902376
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.